China
· Delayed Price · Currency is CNY CSPC Innovation Pharmaceutical Statistics
Total Valuation
CSPC Innovation Pharmaceutical has a market cap or net worth of CNY 43.56 billion. The enterprise value is 43.09 billion.
| Market Cap | 43.56B |
| Enterprise Value | 43.09B |
Important Dates
The next estimated earnings date is Wednesday, October 23, 2024.
| Earnings Date | Oct 23, 2024 |
| Ex-Dividend Date | Apr 25, 2024 |
Share Statistics
CSPC Innovation Pharmaceutical has 1.40 billion shares outstanding. The number of shares has decreased by -4.73% in one year.
| Shares Outstanding | 1.40B |
| Shares Change (YoY) | -4.73% |
| Shares Change (QoQ) | -4.84% |
| Owned by Insiders (%) | 0.00% |
| Owned by Institutions (%) | 11.33% |
| Float | 340.07M |
Valuation Ratios
The trailing PE ratio is 68.37 and the forward PE ratio is 84.72.
| PE Ratio | 68.37 |
| Forward PE | 84.72 |
| PS Ratio | 20.15 |
| PB Ratio | 11.15 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 55.33, with an EV/FCF ratio of -61.36.
| EV / Earnings | 68.65 |
| EV / Sales | 20.24 |
| EV / EBITDA | 55.33 |
| EV / EBIT | 67.47 |
| EV / FCF | -61.36 |
Financial Position
The company has a current ratio of 2.78, with a Debt / Equity ratio of 0.00.
| Current Ratio | 2.78 |
| Quick Ratio | 2.33 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.00 |
| Debt / FCF | -0.00 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 13.45% and return on invested capital (ROIC) is 8.31%.
| Return on Equity (ROE) | 13.45% |
| Return on Assets (ROA) | 7.20% |
| Return on Capital (ROIC) | 8.31% |
| Revenue Per Employee | 1.13M |
| Profits Per Employee | 332,638 |
| Employee Count | 1,887 |
| Asset Turnover | 0.38 |
| Inventory Turnover | 4.61 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +117.86% in the last 52 weeks. The beta is -0.21, so CSPC Innovation Pharmaceutical's price volatility has been lower than the market average.
| Beta (5Y) | -0.21 |
| 52-Week Price Change | +117.86% |
| 50-Day Moving Average | 24.64 |
| 200-Day Moving Average | 28.08 |
| Relative Strength Index (RSI) | 63.77 |
| Average Volume (20 Days) | 9,464,929 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, CSPC Innovation Pharmaceutical had revenue of CNY 2.13 billion and earned 627.69 million in profits. Earnings per share was 0.46.
| Revenue | 2.13B |
| Gross Profit | 920.81M |
| Operating Income | 643.33M |
| Pretax Income | 755.36M |
| Net Income | 627.69M |
| EBITDA | 782.66M |
| EBIT | 643.33M |
| Earnings Per Share (EPS) | 0.46 |
Balance Sheet
The company has 1.48 billion in cash and 1.25 million in debt, giving a net cash position of 1.48 billion or 1.06 per share.
| Cash & Cash Equivalents | 1.48B |
| Total Debt | 1.25M |
| Net Cash | 1.48B |
| Net Cash Per Share | 1.06 |
| Equity (Book Value) | 4.92B |
| Book Value Per Share | 2.80 |
| Working Capital | 1.56B |
Cash Flow
In the last 12 months, operating cash flow was -544.31 million and capital expenditures -157.98 million, giving a free cash flow of -702.28 million.
| Operating Cash Flow | -544.31M |
| Capital Expenditures | -157.98M |
| Free Cash Flow | -702.28M |
| FCF Per Share | -0.50 |
Margins
Gross margin is 43.25%, with operating and profit margins of 30.21% and 29.48%.
| Gross Margin | 43.25% |
| Operating Margin | 30.21% |
| Pretax Margin | 35.48% |
| Profit Margin | 29.48% |
| EBITDA Margin | 36.76% |
| EBIT Margin | 30.21% |
| FCF Margin | -32.98% |
Dividends & Yields
This stock pays an annual dividend of 0.27, which amounts to a dividend yield of 0.80%.
| Dividend Per Share | 0.27 |
| Dividend Yield | 0.80% |
| Dividend Growth (YoY) | 156.00% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 59.60% |
| Buyback Yield | 4.73% |
| Shareholder Yield | 5.53% |
| Earnings Yield | 1.46% |
| FCF Yield | -1.61% |
Stock Splits
The last stock split was on April 25, 2024. It was a forward split with a ratio of 1.2.
| Last Split Date | Apr 25, 2024 |
| Split Type | Forward |
| Split Ratio | 1.2 |
Scores
CSPC Innovation Pharmaceutical has an Altman Z-Score of 22.39.
| Altman Z-Score | 22.39 |
| Piotroski F-Score | n/a |